The basic leucine zipper transcription factor, C/EBPbeta, is critical for growth and differentiation of the mammary gland. Epithelial cell proliferation in early pregnancy and differentiation at late pregnancy are severely impaired in C/EBPbeta null mice, which fail to lactate. Alternative translation of the intronless C/EBPbeta gene produces three different protein isoforms. C/EBPbeta-1 and -2 are transactivators, whereas C/EBPbeta-3 lacks a transactivation domain and inhibits transcription. Although differences between C/EBPbeta-1 and -2 have received little attention, our studies show that they are functionally distinct. Ectopic C/EBPbeta-2 expression transforms mammary epithelial cells (MECs) in vitro. The cells become anchorage independent, undergo an epithelial to mesenchymal transition (EMT), and gain invasive growth characteristics. In contrast, C/EBPbeta-1 expression blocks the invasive growth of metastatic breast cancer cell lines in culture. In this application we propose to examine the mechanistic basis underlying the functional dichotomy in C/EBPbeta-1 vs. -2 expression. These two transactivators differ by only 21 N-terminal amino acids present in C/EBPbeta-1, but absent from C/EBPbeta-2. We hypothesize that C/EBPbeta-1 and -2 undergo isoform-specific posttranslational modifications essential for their different functions. In support of this hypothesis, we have recently shown that C/EBPbeta-1, but not C/EBPbeta-2, is conjugated to the small ubiquitin-like modifier proteins, SUMO2 and SUMO3. We will determine whether SUMO-conjugation is necessary for the inhibition of invasive growth by C/EBPbeta-1. We will also investigate whether SUMO2,3 modification is required for protein-protein interactions with the Swi/Snf chromatin remodeling complex and/or affects the localization of C/EBPbeta-1 is subnuclear speckles. In contrast, C/EBPbeta-2 is targeted by multiple protein kinases, some of which are downstream of Ras activation. Indeed, C/EBPbeta has been shown to be an essential target of oncogenic Ras signaling in skin tumorigenesis and NIH 3T3 transformation. We will examine the requirement for C/EBPbeta-2 phosphorylation by ERKI/2 and p90Rsk-2 in mammary epithelial cell transformation. In human breast cancer, Ras-dependent signaling pathways are often activated by alterations in receptor tyrosine kinases. Therefore, we plan to determine whether receptor tyrosine kinase activation will synergize with C/EBPbeta-2 in transforming mammary epithelial cells. Because C/EBPbeta-2 promotes, whereas C/EBPbeta-1 inhibits, the invasive growth of MECs, misregulated expression of these two transactivator isoforms could contribute to growth and metastasis in breast cancer. Interestingly, C/EBPbeta-2 is undetectable in normal human breast tissue (obtained from reduction mammoplasty) where only C/EBPbeta-1 is expressed. However, 60% of primary breast tumors examined showed a high level of C/EBPbeta-2 expression, and moderate expression was detected in another 30% of the samples. Moreover, all breast cancer cell lines in culture express C/EBPbeta-2, but none express C/EBPbeta-1. We have recently generated mice carrying an MMTV-driven C/EBPbeta-2 transgene, and significantly, virgin females exhibit precocious, hyperplastic mammary gland development. We will continue to study these animals to determine if females with hyperplasia go on to develop neoplasia and/or have accelerated development of metastatic carcinoma when crossed with other mouse models of breast cancer. Once cancer cells have metastasized, breast cancers are largely incurable even with state-of-the-art approaches. These studies will provide important insights into how misregulated C/EBPbeta isoform expression may contribute to the development of metastatic mammary carcinoma.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM069634-04
Application #
7173867
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Tompkins, Laurie
Project Start
2004-02-01
Project End
2009-01-31
Budget Start
2007-02-01
Budget End
2009-01-31
Support Year
4
Fiscal Year
2007
Total Cost
$293,510
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Physiology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212